TP53 and breast carcinoma: These are linked to high mutation rates in the homologous recombination genes tumor protein 53 (TP53) and the somatic and germline breast cancer gene 1/2 (BRCA1/2). The choice of the best-targeted therapy can be influenced by determining the particular mutational makeup of cancer [5].